Home › Companies › 10X GENOMICS INC. › 2023-2024

10X GENOMICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and 10X GENOMICS INC.’s Form 8-K, filed 2024-06-13 (Item 5.07 on EDGAR). Page generated 04 October 2026.

4Ballot items
350Asset managers
1,574Fund votes
2024-06-11Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore 10X GENOMICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by 10X GENOMICS INC.

These tallies are 10X GENOMICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

10X GENOMICS INC. — official shareholder meeting results, meeting held 2024-06-11
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Kimberly J. Popovits	198,553,136	18,689,301	125,755	--	11,864,638	Majority: yes
Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year	228,845,897	174,119	212,814	--	--	Majority: yes
Proposal 3 - Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval The Company's stockh	112,727,437	104,506,389	134,366	--	11,864,638	Majority: yes
Proposal 4 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as descr	180,775,070	36,417,839	175,283	--	11,864,638	Majority: yes

Source: 10X GENOMICS INC., Form 8-K, filed with the SEC on 2024-06-13 — read the filing on EDGAR.

How asset managers voted at the 10X GENOMICS INC. 2023-2024 meeting

Each item below shows how the 350 asset managers that disclosed a 10X GENOMICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 180,775,070AGAINST: 36,417,839

10X GENOMICS INC.’s own tally for this item (“Proposal 4 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executi”): 180,775,070 for, 36,417,839 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 345 asset managers below cast 58% of the shares they voted on this item FOR (63,956,911 for, 45,375,814 against).

FOR 58%AGAINST 41%

FOR: 63,956,911 (58.2%)AGAINST: 45,375,814 (41.3%)ABSTAIN: 533,752 (0.5%)NOT VOTED: 9,803 (0.0%)UNKNOWN: 46 (0.0%)

Largest asset managers voting on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and” at 10X GENOMICS INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	30,394,489	1,571,016	For
Vanguard	9,088,217	1,436,878	For
T. Rowe Price	3,530,904	5,718,030	Against
ARK ETF Trust	6,004,325	0	For
Morgan Stanley	5,073,601	5,806	For
BlackRock	60,877	4,248,063	Against
BAILLIE GIFFORD & CO LTD	0	3,850,099	Against
Nikko Asset Management Americas, Inc.	0	3,816,669	Against
SANDS CAPITAL MANAGEMENT, LLC	2,288,051	0	For
BAILLIE GIFFORD OVERSEAS LTD	0	1,889,073	Against
Charles Schwab	0	1,885,412	Against
GEODE CAPITAL MANAGEMENT, LLC	0	1,635,730	Against
BROWN CAPITAL MANAGEMENT LLC	0	1,598,610	Against
Capital Group	43	1,586,600	Against
UBS	0	1,354,213	Against
Brown Capital Management Mutual Funds	0	1,249,511	Against
RTW INVESTMENTS, LP	1,208,066	0	For
Putnam	0	1,008,196	Against
GENERATION INVESTMENT MANAGEMENT LLP	0	975,905	Against
FRANKLIN ADVISERS INC	0	823,336	Against
Freshford Capital Management, LLC	781,907	0	For
State Street	727,579	43,437	For
Voya	575,974	120,803	For
TOUCHSTONE FUNDS GROUP TRUST	691,105	0	For
FRANKLIN STRATEGIC SERIES	0	648,000	Against

Showing the 25 largest of 345 asset managers. See all 345 in the interactive database.

2. A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our board of directors without requiring stockholder approval;

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

51.9% Majority: yes · of votes cast

FOR 51.9%AGAINST 48.1%

FOR: 112,727,437AGAINST: 104,506,389

10X GENOMICS INC.’s own tally for this item (“Proposal 3 - Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval ”): 112,727,437 for, 104,506,389 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 77 asset managers below cast 24% of the shares they voted on this item FOR (11,455,634 for, 35,722,858 against).

FOR 24%AGAINST 76%

FOR: 11,455,634 (24.3%)AGAINST: 35,722,858 (75.7%)

Largest asset managers voting on “A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our b” at 10X GENOMICS INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	0	14,977,374	Against
Vanguard	1,436,878	8,948,111	Against
ARK ETF Trust	6,004,325	0	For
T. Rowe Price	0	3,881,668	Against
BlackRock	0	1,706,915	Against
Morgan Stanley	0	1,614,212	Against
Brown Capital Management Mutual Funds	1,249,511	0	For
Charles Schwab	940,460	0	For
Capital Group	0	793,300	Against
TOUCHSTONE FUNDS GROUP TRUST	0	691,105	Against
FRANKLIN STRATEGIC SERIES	648,000	0	For
Columbia Threadneedle	0	418,141	Against
BNY Mellon	0	408,754	Against
ALGER FUNDS	0	360,492	Against
Transamerica	0	297,184	Against
Voya	0	287,987	Against
TIAA	249,365	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	0	240,000	Against
Equitable	0	197,293	Against
Putnam	191,656	0	For
AMERICAN BEACON FUNDS	158,214	0	For
Jackson National	10,633	132,924	Against
Russell Investments	138,599	0	For
Brighthouse	0	131,732	Against
John Hancock	0	117,462	Against

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

3. Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to serve a three-year term expiring at the 2027 annual meeting of stockholders or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal; Kimberly J. Popovits

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 198,553,136AGAINST: 18,689,301

10X GENOMICS INC.’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 198,553,136 for, 18,689,301 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 77 asset managers below cast 85% of the shares they voted on this item FOR (40,144,209 for, 7,034,283 against).

FOR 85%AGAINST 15%

FOR: 40,144,209 (85.1%)AGAINST: 7,034,283 (14.9%)

Largest asset managers voting on “Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to se” at 10X GENOMICS INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	13,458,118	1,519,256	For
Vanguard	10,384,989	0	For
ARK ETF Trust	6,004,325	0	For
T. Rowe Price	0	3,881,668	Against
BlackRock	1,706,915	0	For
Morgan Stanley	1,614,212	0	For
Brown Capital Management Mutual Funds	1,249,511	0	For
Charles Schwab	940,460	0	For
Capital Group	793,300	0	For
TOUCHSTONE FUNDS GROUP TRUST	691,105	0	For
FRANKLIN STRATEGIC SERIES	648,000	0	For
Columbia Threadneedle	418,141	0	For
BNY Mellon	0	408,754	Against
ALGER FUNDS	0	360,492	Against
Transamerica	259,375	37,809	For
Voya	287,987	0	For
TIAA	0	249,365	Against
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	240,000	0	For
Equitable	149,465	47,828	For
Putnam	191,656	0	For
AMERICAN BEACON FUNDS	158,214	0	For
Jackson National	62,559	80,998	Against
Russell Investments	138,599	0	For
Brighthouse	110,630	21,102	For
John Hancock	0	117,462	Against

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

4. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 228,845,897AGAINST: 174,119

10X GENOMICS INC.’s own tally for this item (“Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the C”): 228,845,897 for, 174,119 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 77 asset managers below cast 100% of the shares they voted on this item FOR (47,178,492 for, 0 against).

FOR 100%

FOR: 47,178,492 (100.0%)

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at 10X GENOMICS INC., 2023-2024
Asset manager	For	Vote
Fidelity	14,977,374	For
Vanguard	10,384,989	For
ARK ETF Trust	6,004,325	For
T. Rowe Price	3,881,668	For
BlackRock	1,706,915	For
Morgan Stanley	1,614,212	For
Brown Capital Management Mutual Funds	1,249,511	For
Charles Schwab	940,460	For
Capital Group	793,300	For
TOUCHSTONE FUNDS GROUP TRUST	691,105	For
FRANKLIN STRATEGIC SERIES	648,000	For
Columbia Threadneedle	418,141	For
BNY Mellon	408,754	For
ALGER FUNDS	360,492	For
Transamerica	297,184	For
Voya	287,987	For
TIAA	249,365	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	240,000	For
Equitable	197,293	For
Putnam	191,656	For
AMERICAN BEACON FUNDS	158,214	For
Jackson National	143,557	For
Russell Investments	138,599	For
Brighthouse	131,732	For
John Hancock	117,462	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

Largest 10X GENOMICS INC. shareholders voting in 2023-2024

Ranked by the number of 10X GENOMICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 119,095,362 shares outstanding at the time of that meeting.

Top 10X GENOMICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Fidelity	26.84%
2	Vanguard	8.84%
3	T. Rowe Price	7.77%
4	ARK ETF Trust	5.04%
5	Morgan Stanley	4.26%
6	BlackRock	3.62%
7	BAILLIE GIFFORD & CO LTD	3.23%
8	Nikko Asset Management Americas, Inc.	3.20%
9	SANDS CAPITAL MANAGEMENT, LLC	1.92%
10	BAILLIE GIFFORD OVERSEAS LTD	1.59%

Reported 10X GENOMICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

10X GENOMICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	11.15%	13F
BlackRock	7.94%	13F
FMR (Fidelity)	7.10%	13F
T. Rowe Price	3.07%	13F
Morgan Stanley	2.37%	13F
Goldman Sachs	2.25%	13F
Geode Capital	1.38%	13F
State Street	1.33%	13F
Millennium Management	0.98%	13F
JPMorgan Chase	0.90%	13F

Percentages above are of 119,095,362 shares outstanding, as reported by 10X GENOMICS INC. on its Form 10-K dated 2023-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10X GENOMICS INC.’s 10-K dated 2023-12-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At 10X GENOMICS INC.'s shareholder meeting held 2024-06-11, in the 2023-2024 proxy season, 350 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,574 separate fund positions. On the most widely held item on that ballot — A vote to approve, on a non-binding, advisory basis, the compensation of our named executive… — FOR was 83% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: 10X GENOMICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-13.

10X GENOMICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.